Grifols SA (Grifols) is a pharmaceutical and chemical manufacturing company engaged on enhancing the health and well-being of patients worldwide. It is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.
Headquarters
Spain
Address
C/ Jesus Y Maria, 6, Barcelona, 08022
Telephone
34 935 710000
No of Employees
23,233
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GRF (MCE)
Revenue (2021)
$5.8B
-7.6%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-70.4%
(2021 vs 2020)
Market Cap*
$12.3B
Net Profit Margin (2021)
XXX
-68.0%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Bioscience: | Albutein |
| Plasma Derivative Products | Alphanate |
| Diagnostic: | Anbinex |
| XXX | XXX |
| XXX | XXX |
| XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Acquisitions/Mergers/Takeovers | In April, the company announced the completion of the acquisition of 100% stake of Tiancheng (Germany) Pharmaceutical Holdings AG. |
| 2022 | Contracts/Agreements | In March, the company partnered with Feeding America to help "box out hunger" by collecting nonperishable food and raising money for local member food banks across the country. |
| 2022 | Contracts/Agreements | In February, the company entered into a global collaboration and licensing agreement with Endpoint Health for exclusive rights to develop and commercialize Antithrombin III (AT-III) in sepsis. |
Competitor Comparison
| Key Parameters | Grifols SA | Takeda Pharmaceutical Co Ltd | CSL Ltd | Omnicell Inc | Abeona Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | Spain | Japan | Australia | United States of America | United States of America |
| City | Barcelona | Chuo-Ku | Melbourne | Mountain View | New York |
| State/Province | - | Tokyo | Victoria | California | New York |
| No. of Employees | 23,233 | 47,099 | 25,000 | 3,800 | 90 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Raimon Grifols Roura | Co - Chief Executive Officer; Director | Executive Board | 2017 | - |
| Victor Grifols Deu | Director; Co - Chief Executive Officer | Executive Board | 2016 | - |
| Alfredo Arroyo Guerra | Chief Financial Officer | Senior Management | - | - |
| Maria Teresa Rione | Chief Communications Officer | Senior Management | - | - |
| Albert Grifols Coma-Cros | Chief Scientific Innovation Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer